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Aims Assessment of ECG-features as predictors of sudden death in adults with hypertrophic cardiomyopathy (HCM).
Methods
and results
ECG-amplitude sums were measured in 44 normals, 34 athletes, a hospital-cohort of 87 HCM-patients, and 29 HCM-
patients with sudden death or cardiac arrest (HCM-CA). HCM-patients with sudden death or cardiac arrest had sub-
stantially higher ECG-amplitudes than the HCM-cohort for limb-lead and 12-lead QRS-amplitude sums, and ampli-
tude–duration products (P ¼ 0.00003–P ¼ 0.000002). Separation of HCM-CA from the HCM-cohort is obtained
by limb-lead QRS-amplitude sum  7.7 mV (odds ratio 18.8, sensitivity 87%, negative predictive value (NPV)
94%, P , 0.0001), 12-lead amplitude–duration product  2.2 mV s (odds ratio 31.0, sensitivity 92%, NPV 97%,
P , 0.0001), and limb-lead amplitude–duration product  0.70 mV s (odds ratio 31.5, sensitivity 93%, NPV 96%,
P , 0.0001). Sensitivity in HCM-patients ,40 years is 90, 100, and 100% for those ECG-variables, respectively.
Qualitative analysis showed correlation with cardiac arrest for pathological T-wave-inversion (P ¼ 0.0003), ST-
depression (P ¼ 0.0010), and dominant S-wave in V4 (P ¼ 0.0048). A risk score is proposed; a score  6 gives a sen-
sitivity of 85% but a higher positive predictive value than above measures. Optimal separation between HCM-CA
,40 years and athletes is obtained by a risk score  6 (odds ratio 345, sensitivity 85%, speciﬁcity 100%, P , 0.0001).
Conclusion Twelve-lead ECG is a powerful instrument for risk-stratiﬁcation in HCM.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Hypertrophic cardiomyopathy (HCM) is the commonest medical
causeofsudden unexpected deathinolderchildren
1 and in athletes.
2
The prevalence of the disease in young adults is approximately 1 in
500.
3 Studies in adult HCM patients have identiﬁed some risk
factors for sudden death: non-sustained ventricular tachycardia
(VT) on 24 h ECG, left ventricular (LV) hypertrophy, in particular a
maximal wall thickness .3 cm, malignant family history, syncope,
and a hypotensive blood pressure response on exercise testing, all
compared by Elliot et al.,
4 and presence of LV outﬂow tract
obstruction.
5 These risk factors individually have a low positive pre-
dictive accuracy,
6–8 and a search for further risk factors has been
advocated.
9 Recently it was shown that in childhood HCM increased
ECG-amplitudesareasigniﬁcantriskfactorforsuddendeath,whichis
independentofechocardiographicmeasuresofhypertrophy.
10Inthat
study it was found that the QRS-amplitude sum in limb-leads was a
better predictor than Sokolow–Lyon index, with a sensitivity of
94%. The limb-lead QRS-amplitude sum can always be quantiﬁed in
both children and adults, whereas dominant S-waves across precor-
dial leads, invalidating Sokolow–Lyon index, are not rare in HCM.
The odds ratios for this risk factor in children were considerably
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doi:10.1093/eurheartj/ehp443larger (up to 34.3) than other risk factors hitherto described in adult
patients with HCM (relative risks ranging between 1.8 and 5.3).
8
However, childhood-onset HCM has varying aetiology,
11 including
idiopathic cases and children with Noonan’s syndrome, with only
about one-third having familial disease with autosomal dominant
inheritance.
10,12 Thus it is unclear whether these ﬁndings are
relevantforthemorecommonadultformoffamilialHCMduetosar-
comere mutations. Furthermore it is well known that intensive phys-
ical training is associated with an increase in ECG-amplitudes.
13 The
current study was undertaken to evaluate whether ECG-amplitudes
are also a signiﬁcant risk factor for sudden death in adulthood
HCM, and to compare the predictive accuracy of different ECG-
measures. As certain countries, for example Italy, use ECG for com-
pulsory pre-participation screening of athletes we have also assessed
to what extent it is possible to differentiate the ECG-features that
characterize a high risk for sudden death in HCM from ECG ampli-
tudes that could be encountered in normal athletes.
Methods
Normal subjects
Electrocardiograms from consecutively recruited normotensive adult
outpatient attenders that had been referred for cardiological assess-
ment, and had echocardiographic ﬁndings that were normal with
regard to wall thickness, diastolic function, and tissue-Doppler
studies were used as the normal reference group [n ¼ 44, age 29+
8 (mean+SD) years]. In the athlete group competitive endurance ath-
letes that were volunteers from sports clubs for a study correlating
maximal oxygen-uptake and echocardiographic dimensions were
included. The athletes were distance runners or competitive long-
distance swimmers. They had all been competing at a regional or
national level for at least 2 years, although most of them much
longer, (n ¼ 34, age 23+5 years).
Hypertrophic cardiomyopathy patients
All case notes from the Sahlgrenska, Mo ¨lndal, and the O ¨ stra University
Hospitals’ (Gothenburg, Sweden) data bases with the diagnostic codes
for HCM (obstructive and non-obstructive) in patients .17 years of
age were retrieved between January 2002 and September 2008: 129
cases were identiﬁed. Some of these cases had of course been diag-
nosed before 2002. Since these hospitals make up all regional referral
units in Gothenburg, the case-mix reﬂects a geographically based
cohort. Patients that had had a sudden cardiac arrest, or had concomi-
tant signiﬁcant hypertension, surgically induced left bundle-branch block
or ventricular pacing were excluded, leaving a normotensive comparison
cohort with measurable ECGs of 87 patients (52 males, 37 females) with
age at diagnosis 42+17 years, and an average follow-up of 10.2 years.
We have based our calculations on the earliest ECG in the case notes,
i.e. ECG at diagnosis, (since for some individuals with post-mortem diag-
nosis we only had ECGs taken at military conscription). Average
maximal wall thickness in the cohort was 2.0 [95% CI 1.9–2.1] cm.
This Gothenburg HCM-cohort was compared with a group of 29
HCM patients (HCM-CA, age 28+17 years at diagnosis; 23 males, 6
females) with sudden deaths or cardiac arrests occurring at 36+16
years of age. They were retrieved from the hospital records of the Sahl-
grenska, Mo ¨lndal, and the O ¨ stra University Hospitals, Gothenburg, and
the University Hospital in Lund between 2000 and September 2008, as
well as a nationwide study collecting all subjects aged 15–35 years in
Sweden that had undergone a forensic post-mortem for a sudden
cardiac death between 1992 and 1999.
14 The average duration of
follow-up for HCM-CA patients not presenting with sudden death
was 10.9 years, and average maximal wall thickness 2.7 [2.3–3.1] cm.
The group comprised 18 patients where an ECG had been recorded
prior to a subsequent sudden death, and 11 patients where an ICD
had been implanted as secondary prevention after a documented resus-
citated cardiac arrest or a symptomatic VT requiring medical
termination. Two of these patients had pre-arrest ECGs recorded at
different times with and without partial left-bundle branch block; both
types of ECG-morphology were included in the analysis giving 31
ECGs in the sudden-death/cardiac arrest group.
Electrocardiographic features
The measures performed on the averages of three to ﬁve successive
complexes were Sokolow–Lyon index,
15 limb-lead QRS-sum deﬁned
as the sum of RþS-waves (or Q if deeper than S) in all six limb-leads,
12
six chest-lead QRS-sum, 12-lead QRS-sum,
16 12-lead QRS voltage–
duration product,
17 and limb-lead QRS voltage–duration product. In
addition QRS-duration and QTc (using Bazett’s formula) were calcu-
lated. ECGs were also evaluated in respect to the presence of
QRS-axis deviation, pathological Q-waves, T-wave inversion .1 mm,
giant (.10 mm) positive or negative T-waves, ST-depression
.2 mm, and an S-wave.R-wave in V4.
Echocardiographic measures
All subjects included in the normal groups had been assessed with
detailed M-mode and 2-D echocardiography including short-axis
views and detailed Doppler studies, and found to be normal. For
HCM-patients the measurements of wall thickness recorded in the
case notes, and carried out by echocardiography technologists uncon-
nected with the study, were used.
Statistics
This is a retrospective case–control study, but as we were unable to
match on clinical characteristics (as a number of the individuals in the
HCM-CA group were post-mortem diagnoses with mustering ECGs
only) we have elected to avoid selection bias in our comparison
group by using a complete geographical cohort. In addition, we com-
pared speciﬁcally HCM-CA cases with cardiac arrest below the age of
40 years, where coronary artery disease is unlikely to be a contributory
factor, with the HCM-cohort cases with initial ECG below 40 years of
age, which then provides a well age- and gender-matched comparison
group. Statistical analysis was carried out using commercial software
(Statgraphics Plus v5.2 and GraphPad Prism 4, and R freeware version
2.7.2). Comparisons of proportions between the groups were carried
out by two-tailed Fisher’s exact test, and odds ratios and their 95% con-
ﬁdence intervals were calculated. Comparisons between groups were
carried out with Mann–Whitney U-test. Cut-off values for screening
were selected using frequency distribution plots and ROC curves,
with optimal cut-offs selected to prioritise sensitivity over speciﬁcity;
for details of methodology see Supplementary material online, Detailed
Statistical Methodology, and ROC curves in Supplementary material
online, Figures S2 and S3. The calculated absolute values for positive pre-
dictive value (PPV) using these cut-offs are probably overestimates, and
those for negative predictive value (NPV) underestimates, since the
cardiac arrest cohort is recruited from a much larger geographical
base than the Gothenburg HCM-cohort, but the relative ranking in
PPV and NPV between different screening measures will still be valid.
Absolute values of sensitivity and false-positive rate are unaffected by
this and true estimates in the Gothenburg cohort. However, like all esti-
mates based on a single sample they may be overly optimistic. We have
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ﬁdence intervals of the cut-off points proposed to assess their statistical
accuracy. To extract the cut-off point in each bootstrap sample (n ¼
1000) we deﬁned as criterions that sensitivity should be given a
greater weight than speciﬁcity, and that sensitivity and NPV should
equal or exceed that obtained in the Gothenburg cohort; for details
see Supplementary material online, Detailed Statistical Methodology.
Results
The results in all comparative groups are illustrated as mean+95%
CI in Figure 1A and B in order to facilitate cross-comparisons
between groups (the complete summary statistics are given in Sup-
plementary material online, Table S1).
Gender differences in normal individuals
Figure 1A shows that there are no signiﬁcant differences in
QRS-amplitude sum in the six limb-leads between males and
females (P ¼ 0.78), but there are highly signiﬁcant differences in
QRS-amplitude sum from the six chest-leads, with values in
females being lower (P ¼ 0.00001). This leads to signiﬁcantly lower
12-lead QRS-amplitude sums (P ¼ 0.00004), and Sokolow–Lyon
index(P ¼ 0.0005)infemalesthanmales.Asdescribedpreviously,
18
Figure 1 The values of different ECG-measures are represented as staple diagrams, with the 95% CI for the mean given as a bracket. F and M
indicates female vs. male values, white columns are normals, light grey athletes, medium grey the Gothenburg hypertrophic cardiomyopathy
cohort, and dark grey values from the hypertrophic cardiomyopathy patients that had suffered a cardiac arrest. (A) LL QRS, Limb-lead
QRS-amplitude sums, SOKLY, Sokolow–Lyon index; ChL QRS, 6 chest-lead QRS-amplitude sums; 12-L, 12-lead QRS-amplitude sums.
(B) QRS-dur., QRS-duration; QTc, corrected QT-interval; LL-prod., limb-lead amplitude–duration product; 12-L prod., 12-lead amplitude–
duration product.
ECG-amplitudes 441QTc is slightly longer in females (P ¼ 0.029). The 12-lead QRS
amplitude–duration product, which is often used to evaluate LV
hypertrophy, is substantially lower in females than in males (P ¼
0.00001; Figure 1B; see Supplementary material online, Table S1).
Athletes
Figure 1A shows that athletes have the same gender differences,
with signiﬁcantly higher chest-lead sums (P ¼ 0.00006),
Sokolow–Lyon index (P ¼ 0.0003), and 12-lead sums (P ¼
0.0004) in males compared with females, but with no signiﬁcant
gender difference in limb-lead QRS-sums. QRS-duration was sig-
niﬁcantly longer in males (P ¼ 0.04; Figure 1B, see Supplementary
material online, Table S1), which may be partly related to the
fact that they had signiﬁcantly higher maximal oxygen uptake
(4.57+0.46 vs. 3.37+0.52 L/min; mean+SD, P ¼ 0.00008) and
thus almost certainly had hearts with larger diastolic dimensions.
Even related to body size the male athletes in our study had a
larger oxygen uptake, 65.2+4.6 mL/kg BW vs. 53.5+8.9 mL/kg
BW in the females (P ¼ 0.0003). There was a weak correlation
between limb-lead QRS-sum and oxygen uptake/kg BW, but the
scatter was very wide giving a correlation coefﬁcient of only 0.39
(P ¼ 0.012). The longer QRS-durations contributed to the fact
that not only 12-lead amplitude–duration product (P ¼ 0.0002),
but also limb-lead amplitude–duration product (P ¼ 0.01) was
higher in males.
Cohort with hypertrophic
cardiomyopathy
Figure 1A shows a larger spread of ECG-amplitude sums and
Sokolow–Lyon index in all HCM-patients when compared with
controls of the same gender, but they are not signiﬁcantly higher
either in males (P ¼ 0.07–0.78) or in females (P ¼ 0.06–0.19;
see Supplementary material online, Table S1); see Table 1 for
summary statistics of HCM-group. QRS-duration is not increased
in the HCM-cohort, and consequently neither limb-lead ampli-
tude–duration product nor 12-lead amplitude–duration product
is signiﬁcantly different from male or female normal controls
(Figure 1B; see Supplementary material online, Table S1).
Correlations of electrocardiographic
features with known risk factors
Correlation analysis in the Gothenburg HCM-cohort showed that
ECG-features that showed a signiﬁcant positive correlation with
the presence of a documented non-sustained VT on 24 h ECG
............................................................ ........................................................... ............................
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Table 1 Electrocardiographic features in hypertrophic cardiomyopathy with cardiac arrest compared with
hypertrophic cardiomyopathy cohort
ECG
measure
Hypertrophic cardiomyopathy cohort HCM-CA Mann–Whitney
U-test
Male (n 5 52) Female (n 5 35) Male (n 5 24) Female (n 5 7) Male
(P-value)
Female
(P-value)
Age at ECG
(years)
45+16 [41–50] 48+18 [41–54] 32+16 [25–38] 33+19 [15–51] 0.0098 0.037
Limb-lead
QRS-sum
(mV)
6.8+3.2 [6.0–7.7] 6.5+2.0 [5.4–7.5] 11.3+4.6 [9.4–13.2] 11.1+3.5 [7.8–14.4] 0.000003 0.0027
Chest-lead
QRS-sum
(mV)
13.0+4.4 [11.8–14.3] 10.9+3.5 [9.7–12.1] 17.7+5.6 [15.0–20.3] 18.8+6.0 [11.3–26.2] 0.0004 0.0043
12-lead
QRS-sum
(mV)
19.7+6.2 [17.6–22.5] 17.4+5.5 [15.5–19.2] 27.5+7.3 [24.1–30.9] 33.3+11.9 [18.6–48.1] 0.00004 0.0022
12-lead
product
(mV s)
2.01+0.87 [1.76–2.25] 1.59+0.63 [1.36–1.809] 2.88+0.89 [2.46–3.29] 3.59+1.52 [1.70–5.47] 0.00006 0.0024
Limb-lead
product
(mV s)
0.66+0.33 [0.57–0.76] 0.61+0.32 [0.50–0.73] 1.14+0.47 [0.95–1.34] 1.47+0.54 [0.94–2.22] 0.000002 0.0012
Sokolow–
Lyon index
(mV)
2.8+1.0 [2.5–3.1] 2.7+1.0 [2.3–3.1] 4.8+1.9 [3.9–5.7] 6.1+3.2 [2.7–9.4] 0.00002 0.0036
QRS-duration
(ms)
97+14 [93–101] 88+9 [85–91] 101+16 [95–108] 123+39 [82–164] 0.32 0.0065
QTc (ms) 417+38 [406–428] 425+30 [414–436] 446 þ 23 [435–457] 436+30 [405–468] 0.0029 0.064
Risk score 3+3 [2–4] 3+3 [2–4] 8+3 [7–9] 8+3 [5–11] 0.0000002 0.0011
Values are given as mean+SD [95% conﬁdence intervals].
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dominant S-wave in V4 (P ¼ 0.028), and QTc (P ¼ 0.018).
The only feature that correlated with family history of sudden
death was T-wave inversion in the precordial leads (P ¼ 0.013).
Hypertrophic cardiomyopathy with
cardiac arrest
Figure 1A illustrates that HCM-CA patients have substantially higher
ECG-amplitude sums than controls and the HCM-cohort, with
near doubling in limb-lead QRS-sums, but at least in males
smaller increases in chest lead sums; see Table 1 for summary stat-
istics. Males with cardiac arrest, where we have most statistical
power, have compared with Gothenburg HCM-cohort males sig-
niﬁcantly higher limb-lead QRS-amplitude sums, Sokolow–Lyon
index, 12-lead amplitude sums, limb-lead amplitude–duration pro-
ducts, and 12-lead amplitude–duration products; see Table 1. The
QRS-duration is not signiﬁcantly different, but QTc is slightly
longer than in the HCM-cohort. When comparing males with
cardiac arrest with male athletes (Figure 1A and B) only the QTc
(P ¼ 0.00016) and limb-lead derived measures remain signiﬁcantly
different, with higher limb-lead QRS-sums (P ¼ 0.0095) and
Figure 2 The ECG of a 25 year-old female with hypertrophic cardiomyopathy, who suffered a cardiac arrest while rushing to catch a train but
was successfully rescuscitated. Echocardiographically she has moderate hypertrophy with septal thickness 2.5 cm, posterior left ventricular wall
0.8 cm, and maximal wall thickness of 2.6 cm on short-axis and apical views, and there is no dynamic left ventricular outﬂow tract obstruction,
nevertheless there are extensive ST-T-wave abnormalities. Her values on important ECG-measures on her ﬁrst ECG were: limb-lead amplitude
sum ¼ 10.9 mV; limb-lead amplitude–duration product ¼ 0.89 mV s; 12-lead amplitude–duration product ¼ 2.29 mV s; risk score ¼ 8 points;
all above high-risk cut-offs. Sokolow–Lyon index on the other hand is normal, 3.8 mV.
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plementary material online, Table S1). The differences in females
with cardiac arrest follow the same patterns, with if anything
larger increases in ECG-amplitudes compared with normal
controls and athletes than that seen in males with cardiac arrest.
As a number of our HCM-CA subjects were post-mortem diag-
noses, we only have echocardiographic data on maximal wall thick-
ness from case notes on 15 subjects, which ranged between 1.6
and 5.0 cm, mean 2.7 [2.3–3.1] cm, with only three out of
ﬁfteen subjects having a wall thickness .3 cm. This commonly
cited risk factor did not predict well in our study, as the proportion
of HCM-CA cases with wall thickness .3 cm was not signiﬁcantly
higher than in the Gothenburg HCM-cohort with an odds ratio of
5.1 [0.9–26.3], (P ¼ 0.08), and sensitivity was only 20 [4–48] %,
speciﬁcity 95%, PPV 50% and NPV 84%. There was no signiﬁcant
correlation between maximal wall thickness on echocardiography
with limb-lead amplitude sum (P ¼ 0.57), Sokolow–Lyon index
(P ¼ 0.84), 12-lead amplitude–duration product (P ¼ 0.78) or
QRS-duration (P ¼ 0.64). Cox proportional hazards regression
analysis on this subgroup suggests that both ECG-amplitudes and
maximal wall thickness are independent risk factors (limb-lead
QRS-sum P ¼ 0.002, septal thickness P ¼ 0.001). Cox regression
analysis on the total HCM group also suggests that gender does
not come out as separate signiﬁcant risk factor for sudden death,
either when tested against RS-sum at diagnosis (RS-sum P ¼
0.008, gender P ¼ 0.20) or 12-lead product (12-lead product
P ¼ 0.0000, gender P ¼ 0.18). See Supplementary material online,
Results and Figure S1 for more data showing that neither age at
ECG nor gender are signiﬁcant confounders.
Comparing qualitative
electrocardiographic features
Supplementary material online, Table S2 shows the relative fre-
quency of abnormalities in ECG morphology. The HCM-CA
group shows a signiﬁcantly increased occurrence of pathological
T-wave inversion in any lead (P ¼ 0.0003), precordial T-wave
inversion (P , 0.0001), ST-depression (P ¼ 0.0010), and a
dominant S-wave in V4 (P ¼ 0.0048) compared with the
Gothenburg HCM-cohort. QRS-axis deviation is possibly increased
(P ¼ 0.05). On the other hand, the frequency of bundle-branch
block, pathological Q-waves, or giant negative or giant positive
T-waves were not signiﬁcantly different between the groups.
Figure 2 illustrates the repolarization abnormalities often present
in young HCM-patients with cardiac arrest.
Risk score
In order to be able to quantify the number of ECG-abnormalities
present, a risk score was constructed (Table 2) including both
quantitative and qualitative risk features shown to be correlated
with the risk for a cardiac arrest/sudden death (see Supplementary
material online, Development of Risk Score for method). The risk
score showed a signiﬁcant correlation with presence of documen-
ted VT in the Gothenburg HCM-cohort (P ¼ 0.0030). The risk
score in HCM-patients with no documented VT averaged 2 [2–
3], vs. 5 [3–6] in patients with VT on Holter-monitoring (P ¼
0.0006). Among 12 patients in the HCM-cohort with a risk
score  6, six had had a potentially life-threatening arrhythmia
documented. In the HCM-CA group the risk score averaged
8 [6–9], range 1–12.
All hypertrophic cardiomyopathy-groups
combined
Varying degrees of obesity had little inﬂuence on limb-lead
ECG-amplitudes in HCM-patients as there were no correlations
with body mass index (BMI) for limb-lead amplitude sum
(r ¼ 20.12, P ¼ 0.51) or limb-lead amplitude–duration product
(r ¼ 20.12, P ¼ 0.47).
Screening performance of
electrocardiographic measures
When dealing with an outcome that is potentially fatal, it would
seem best to use screening cut-offs that maximize sensitivity and
NPV, at the expense of a lower speciﬁcity. Table 3 shows that
the best single screening measures in terms of sensitivity for
both sexes are limb-lead QRS-amplitude sum  7.7 mV (odds
ratio 18.8, P , 0.0001), 12-lead amplitude–duration product
 2.2 mV s (odds ratio 131.0, P , 0.0001), and limb-lead ampli-
tude–duration product  0.7 mV s (odds ratio 31.5, P , 0.0001).
A wider range of cut-offs in both genders, and in all ages compared
with age   40 years, are illustrated for possible additional screen-
ing measures in Supplementary material online, Table S3. The
highest PPV is obtained by a risk score  6 points (Table 3),
which also has the largest area under the curve (0.89) in the
ROC curves (see Supplementary material online, Figure S2). The
calculated absolute values for PPV may be overestimates, as men-
tioned in Statistics, but the relative ranking in PPV between different
screening measures will still be valid. However, if the above ampli-
tude cut-offs were applied to ECG-screening in athletes there
Table 2 Electrocardiographic scoring system to
assess risk
Any deviation in QRS-axis 1 point
Pathological T-wave inversion
limb leads
1 point
Pathological T-wave inversion
precordial leads
a
2 points
ST-segment depression  2 mm 2 points
Dominant S in V4 2 points
Limb-lead QRS-amplitude sum  7.7 mV 1 point
 10.0 mV 2 points
 12.0 mV 3 points
12-lead amplitude–duration
product
 2.2 mV s 1 point
 2.5 mV s 2 points
 3.0 mV s 3 points
QTc  440 ms 1 point
Max score ¼ 14
QTc ¼ corrected QT-interval.
aThe two points for precordial T-wave inversion does not get added on top of the
1 point for limb-lead T-wave inversion, thus total score available for T-wave
abnormalities is 2 points.
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athletes. ROC-curve analysis suggests that the most useful single
screening measure in athletes with an acceptable speciﬁcity is
limb-lead amplitude–duration product at the higher cut-off of
 0.90 mV s which has a speciﬁcity of 85%, whereas sensitivity
for HCM-patients at risk for cardiac arrest drops to 79%, and an
area under the ROC curve of 0.90. However limb-lead QRS-sum
at the same cut-off as is optimal in children, namely  10 mV,
has the higher speciﬁcity of 88%, and a sensitivity of 70%. A
more useful screening measure for athletes is a risk score  6
points, which has a speciﬁcity of 100% and a sensitivity of 85%,
and an area under the ROC curve of 0.96 (Table 4 and Supplemen-
tary material online, Figure S3). Twelve-lead sums and 12-lead
amplitude–duration product values have large overlaps between
athletes and HCM-patients with cardiac arrest with sensitivity of
only 30% for 12-lead product at a cut-off that optimises speciﬁcity
(Figure 1A and B; Table 4); thus they would appear of little value in
screening athletes.
Bootstrapping assessment of cut-offs
and sensitivity
As shown in Tables 3 and 4, the 95% conﬁdence intervals for the
cut-offs obtained by bootstrapping are fairly symmetrically spread
on both sides of the cut-offs we propose for both limb-lead
QRS-sum [6.5–9.7 mV] and 12-lead product [1.8–2.5 mV s].
...............................................................................................................................................................................
Table 3 Screening performance of the ECG-measures that discriminates best, comparing hypertrophic
cardiomyopathy cohort with hypertrophic cardiomyopathy with cardiac arrest, [with the 95% CI]
ECG measure Cut-off Sens. (%) Spec. (%) PPV (%) NPV (%) Odds ratio Fisher’s
(P-value)
Cohort-estimates
Limb-lead QRS sum (mV), both
genders
7.7 [6.5–9.7] 87 [70–96] 74 [66–95] 54 [39–68] 94 [86–98] 18.8 [5.9–59.5] ,0.0001
12-lead product (mV s), both
genders
2.20 [1.8–2.5] 92 [74–99] 73 [62–82] 50 [35–65] 97 [89–100] 31.0 [6.7–142] ,0.0001
Limb-lead product (mV s), males 0.70 92 [73–99] 69 [54–80] 60 [42–75] 94 [81–99] 24.2 [5.0–117] ,0.0001
Limb-lead product (mV s), males 0.77 83 [63–95] 79 [65–89] 65 [45–81] 91 [79–98] 18.6 [5.3–65.9] ,0.0001
Limb-lead product (mV s), females 0.70 100 [55–100] 72 [53–86] 40 [16–68] 100 [85–100] 32.2 [1.6–630] 0.0018
Limb-lead product (mV s), females 0.77 100 [54–100] 77 [60–90] 43 [18–71] 100 [87–100] 42.1 [2.1–827] 0.0007
Limb-lead product (mV s), both
genders
0.70 [0.70–0.89] 93 [78–99] 69 [58–79] 54 [39–68] 96 [88–100] 31.5 [6.9–143] ,0.0001
Risk score, both genders  6 [6–8] 84 [66–95] 85 [75–91] 67 [50–81] 93 [85–98] 28.4 [9.2–87.5] ,0.0001
Sens., sensitivity; Spec., speciﬁcity; PPV, positive predictive value; NPV, negative predictive value; see Table 2 for deﬁnition of risk score.
Bootstrap estimates of the 95% CI of cut-off is given within bold brackets (B ¼ 1000).
...............................................................................................................................................................................
Table 4 Screening performance of ECG-measures at various cut-offs, comparing athletes with hypertrophic
cardiomyopathy with cardiac arrest age <40 years, [with 95% CI]
ECG measure Cut-off Sens. (%) Spec. (%) PPV (%) NPV (%) Odds ratio Fisher’s
(P-value)
Cohort-estimates
Limb-lead QRS sum (mV),
both genders
10.0 [7.67–12.10] 70 [46–88] 88 [73–97] 78 [52–94] 83 [67–94] 17.5 [4.2–72.1] ,0.0001
12-lead product (mV s),
both genders
3.0 [2.15–4.50] 50 [21–73] 94 [80–99] 78 [ 40–91 82 [64–91] 14.0 [2.4–80.8] 0.0019
12-lead product (mV s),
both genders
3.5 [2.15–4.50] 36 [13–65] 100 [90–100] 100 [90–100] 79 [64–90] 40.0 [2–789] 0.0012
Limb-lead product (mV s),
both genders
0.90 [0.89–1.29] 79 [ 54–94] 85 [69–95] 75 [51–91] 88 [72–97] 42.0 [7.6–232] ,0.0001
Limb-lead product (mV s),
both genders
1.00 [0.89–1.29] 65 [38–86] 91 [76–98] 79 [49–95] 84 [68–94] 18.9 [4.0–89] ,0.0001
Risk score, both genders .6 [3–8] 85 [62–97] 100 [90–100] 100 [80–100] 92 [78–98] 345 [16.9–7064] ,0.0001
Sens., sensitivity; Spec., speciﬁcity; PPV, positive predictive value; NPV, negative predictive value; see Table 2 for deﬁnition of risk score.
Bootstrap estimates of the 95% CI of the cut-off values with sensitivity given equal weight to speciﬁcity are given within bold brackets (B ¼ 1000).
ECG-amplitudes 445The exception is the limb-lead product, where we elected to
propose a cut-off of 0.7 mV s, which is at the lower end of the
95% CI for the whole cohort [0.70–0.89 mV s]; that choice is
based on the fact that the cut-off of 0.77 mV s suggested by the
ROC curve in combined genders had both signiﬁcantly lower sen-
sitivity and a lower odds ratio than 0.7 mV s in males (Table 3), and
as males constitute the majority of sudden deaths we chose the
cut-off that optimized sensitivity for males, accepting some loss
in speciﬁcity. Further details of bootstrapping estimates are given
in Supplementary material online, Tables S4 and S5. It is of note
that the average estimates of sensitivity obtained from our boot-
strapping procedure for the above measures are all within 1–3%
of the average values in Table 3, thus they give no reason to
suppose that the sensitivity estimates in our cohort group are
unduly optimistic; see Further Results of Bootstrapping for details.
Screening performance of
electrocardiographic measures in young
hypertrophic cardiomyopathy patients
As the Gothenburg HCM-cohort had a higher average age than the
patients that died suddenly, we have also compared the ECG-
measures of HCM-cohort patients  40 years of age (age at diag-
nosis 25+10 years) with HCM-patients that had their cardiac
arrest at age   40 years (age at diagnosis 20+9, age at arrest
26+5 years); see Supplementary material online, Table S3 for
details and 95% CI. This comparison shows that all the three
best screening measures have still higher sensitivity and odds
ratios in young adults: 90% sensitivity and odds ratio 27.0 ([5.0–
147]: P , 0.0001) for limb lead sum  7.7 mV; sensitivity of
100% and odds ratio 51.7 ([2.8–959]; P , 0.0001) for 12-lead
amplitude–duration product  2.2 mV s; and 100% sensitivity and
odds ratio of 76.0 ([4.1–149]; P , 0.0001) for limb-lead ampli-
tude–duration product  0.7 mV s. In this age range too, a risk
score  6 points has the highest PPV.
Discussion
Comparison with performance of current
risk-stratiﬁcation strategies
Sudden cardiac death due to arrhythmia is a signiﬁcant cause of
death in both adults and children with HCM,
1,2,14,19 but the risk
factors that have hitherto been identiﬁed in adults (see Introduc-
tion) each individually have low predictive accuracy (relative risks
around 1.8–5.3).
6–8 To have an accurate risk-stratiﬁcation is
important not only in consideration of medical therapy, but
because treatment with an implantable cardiac deﬁbrillator (ICD)
offers a way of protecting high-risk HCM patients from death by
acute ventricular ﬁbrillation.
20 However, the procedure has a
large impact on quality of life, affects employment opportunities,
and has both morbidity and a mortality.
20 Current algorithms for
predicting high-risk HCM-patients are not working ideally as
shown by a study on 103 HCM-patients with particularly severe
cardiac hypertrophy (LV wall thickness .3 cm), where there
were 13 sudden deaths among 87 patients without ICD, whereas
there were no device discharges among any of 11 patients that
had had ICD implantation for primary prevention.
21 It is also
illustrated by a review of studies from large tertiary HCM
centres describing annual appropriate ICD-discharge rates in
HCM-patients of about 0.1% (range 0.05–0.2%; calculation based
on total patient population rather than just patients with ICD),
when compared with annual sudden death rates of 0.9–2.0%.
22
Thus there is an approximate 1:10 ratio between appropriate ICD-
discharges and sudden cardiac deaths, which testiﬁes to current
difﬁculties in selecting the correct patients for ICD implantation.
Whereas the annual appropriate discharge rate is 10.6% for
patients receiving an ICD for secondary prevention (i.e. after a
resuscitated cardiac arrest), the annual discharge rate is only
3.6% in patients having an ICD for primary prevention.
20 Thus,
appropriate selection of patients for this therapy remains incom-
pletely resolved, and identiﬁcation of additional independent risk
factors would likely aid risk-stratiﬁcation and patient selection.
9
Electrocardiographic amplitudes
as risk predictors
Children have a higher risk of sudden death in HCM than adults,
23
and therefore offer higher statistical power to detect new risk
factors. Electrocardiographic amplitudes measured as limb-lead
amplitude sums have been shown to be a powerful predictor of
risk for sudden death, but not for heart failure-related death, in
childhood HCM, with odds ratio of 8.4 for the ECG at diagnosis,
and 34.3 for the ECG closest to the time of death, and surprisingly
this risk factor was independent of echocardiographic wall thick-
ness, which was, as in adults, an additional signiﬁcant risk
factor.
10 Electrocardiographic amplitudes in relation to risk for
death in general in adult HCM-patients, not speciﬁcally sudden
cardiac death, has only been explored in one previous study.
24
This found only a weak correlation between 12-lead amplitude
sum and degree of cardiac hypertrophy, but did not compare
12-lead amplitude sum in survivors and non-survivors; in any
case 33% of the deaths were not sudden deaths, which might pre-
clude detection of risk factors speciﬁc for sudden deaths.
24 The
current study in contrast, focuses on risk factors in adult HCM
patients for sudden death/cardiac arrest only. It conﬁrms that, as
in childhood HCM, the limb-lead QRS-amplitude sum is a highly
signiﬁcant risk factor for sudden death, although for non-athletes
the optimal high-risk cut-off is a lower voltage than in childhood
HCM, with  7.7 mV in adult HCM (giving an odds ratio of 18.8
in the whole group, and 27.0 in patients  40 years of age;
Table 3 and Supplementary material online, Table S3) compared
with the high-risk cut-off of .10 mV in childhood HCM.
10
A new ﬁnding is the fact that increased QRS-duration is an
additional risk factor, which results in the amplitude–duration pro-
ducts discriminating high-risk status in adult HCM even better than
amplitude sums, with 12-lead amplitude–duration product
 2.2 mV s giving an odds ratio for sudden death of 31.0 (51.7 in
 40 year olds), and limb-lead amplitude–duration product
 0.7 mV s giving an odds ratio of 31.5 (76.0 in  40 year olds).
One might assume that large ECG-amplitudes simply reﬂect a gen-
eralized cardiac hypertrophy, but although an association with
echocardiographic wall thickness exists for some measures,
24 it is
very weak, and we found no association between wall thickness
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where we had echocardiographic wall thickness measurements
the wall thickness was an independent risk factor from
ECG-amplitudes, just as we previously found in childhood-HCM.
10
The same has been reported in some adult familial HCM with
marked myocyte disarray on histology due to a Troponin T-
mutation, where many members had no increased wall thickness
on echocardiography or post-mortem, but ‘LV hypertrophy’ on
ECG and a high rate of sudden death.
25,26 The illustrated ECG
has a limb-lead ECG-amplitude sum of 12.4 mV, well above the
high-risk cut-off in our study.
25 It is known that electrocardio-
graphic phenotypes such as Sokolow–Lyon voltage show heritabil-
ity.
27 We have shown here, by absent correlation between
ECG-measures and wall thickness, age and obesity in our
HCM-groups, that in HCM-patients a raised ECG-amplitude sum
is a phenotypic characteristic affected by additional unidentiﬁed
factors, and at least one of these factors has a strong correlation
with risk of fatal arrhythmia. Not much is known about the associ-
ation between ECG voltages and particular HCM mutations, but in
a family with beta-myosin heavy chain mutations and two sudden
deaths (Asp778Glu mutation) 40% of family members had
increased Sokolow–Lyon index,
28 and patients with mutations in
the gamma-2 subunit of AMP-activated protein kinase have strik-
ingly large ECG amplitudes even when hypertrophy is very
mild.
29 One could also speculate that in some circumstances strik-
ingly large ECG-amplitudes may reﬂect inheritance of a
co-malignant factor other than the sarcomeric protein mutation,
possibly ion-channel mutations or factors determining degree of
myocyte disarray.
T-wave changes and risk of sudden death
Surprisingly, few previous studies appears to have examined the
association of T-wave changes with the risk of sudden death.
A Japanese study found that T-wave alternans correlated with
risk for ventricular arrhythmias, and with particularly marked myo-
cardial disarray on histology,
30 and T-wave complexity assessed
with principal component analysis showed that increased complex-
ity correlated with risk for syncope in HCM (Yi et al., 1998
31).
Maron et al.
32 found no signiﬁcant difference in ‘ST-T-wave
changes’ between cardiac arrest victims and a tertiary centre
referred HCM-cohort, but they had made no attempt at analysing
different types of ST-T-wave alterations separately, and we found
particularly strong correlations with precordial T-wave negativity
and ST-segment depression, and no correlation with giant
T-waves (see Supplementary material online, Table S2). Patients
with Troponin T-mutations with high incidence of sudden death
and marked myocardial disarray also have marked T-wave
changes in both limb leads and precordially as shown by
ECG-illustrations, even when hypertrophy is minimal.
25 Thus, a
reasonable interpretation would be that T-wave changes, particu-
larly when seen in young normotensive HCM-patients, may be a
marker for myocardial disarray and denote a high susceptibility
to arrhythmia.
Our results pinpointing ECG-amplitudes and morphology on
ordinary 12-lead ECG, a test available in every district hospital,
as signiﬁcant risk factors for sudden death in HCM that can be
recognized already at the ﬁrst consultation, offers a simple and
convenient approach for selecting individuals at increased risk of
sudden death for accelerated investigations and early appropriate
therapy. Our proposed risk score offers an approach of combining
ECG-amplitude risk factors with qualitative risk factors; the risk
score does not increase sensitivity when compared with ampli-
tude–duration products, but does increase the positive predictive
accuracy.
Gender differences
Male gender is associated with higher risk of sudden cardiac deaths
in general,
14,33 and sudden deaths in athletes,
34 and in young adults
with HCM, where male:female ratios in sudden deaths between
2.8:1 and 10:1 have been reported.
14,19 It is therefore not surpris-
ing that our sample of females with sudden death/cardiac arrest is
smaller than that of males (M/F ratio 3.8). In keeping with earlier
studies we also found a longer QTc in our female normal subjects,
as well as in our female athletes (Figure 1B).
18
There are known gender differences in the sensitivity of various
ECG-voltage criteria for detection of LV hypertrophy.
35 That the
differences are caused by signiﬁcant differences in chest-lead ampli-
tudes only, resulting in signiﬁcant gender differences in the 12-lead
amplitude sums and Sokolow–Lyon index, but not in limb-lead
amplitudes (Figure 1A), is a new ﬁnding. Thus for risk-stratiﬁcation
gender-appropriate cut-offs should be used, or one should use the
limb-lead voltages which do not differ between the gender.
Pre-participation screening of athletes
Pre-participation screening of athletes is compulsory in Italy, and
appears largely effective in detecting individuals with HCM
36 with
a concomitant reduction in sudden deaths caused by cardiomyopa-
thy.
37 The Italian screening programme incorporates a 12-lead
ECG in all tested individuals, but the criteria for abnormality are
not differentiated for gender and are based on single-lead ampli-
tudes, mostly chest-lead criteria.
37 Athletes are known to have
larger ECG-amplitudes than sedentary subjects, and male athletes
show higher ECG-amplitudes than females (Figure 1A and B).
13 It
would therefore appear that pre-participation ECG-screening of
athletes could potentially be made more speciﬁc and sensitive by
either using gender-speciﬁc voltage criteria, or by incorporating
the six limb-lead amplitude sum which is gender-neutral in
normal subjects, and which might help detect HCM-patients at
high risk for sudden death. If one prioritizes speciﬁcity, to avoid
too many false-positives, our results suggest that a suitable
cut-off for pre-participation screening of athletes, leading to con-
sideration of echocardiographic examination, might be a limb-lead
QRS-sum .10 mV, the same cut-off that delineates high-risk status
in children with known HCM, and/or a limb-lead amplitude–dur-
ation product at the higher cut-off of .0.9 mV s which retains a
fair sensitivity of 79% for HCM-associated cardiac arrest. A risk
score  6 has both high sensitivity (85%) and higher speciﬁcity
(100%) and PPV, than either of the above. As it has a clearly
better area under the ROC curve (0.96) than the other measures,
it would appear to be the best approach for screening athletes (see
Supplementary material online, Figure S3 for comparative ROC
curves).
ECG-amplitudes 447Limitations of the study
As a number of our subjects had post-mortem diagnosis only, with
ECGs retrieved from military conscription records, we do not have
complete echocardiographic data to formally test whether
ECG-amplitudes in adult HCM patients are an independent risk
factor for sudden death when compared with maximal wall thick-
ness in the whole cohort, like it is in childhood HCM.
10 However,
the lack of correlation between maximal wall thickness and
ECG-amplitudes both in those patients with sudden death where
we do have echocardiographic data and in the total HCM-group,
and Cox regression analysis in this group, strongly suggest that
they do indeed represent independent risk factors even in adults.
For the same reason, we cannot formally compare
ECG-amplitudes as risk factor with other recognized clinical risk
factors. To establish accurate PPV and NPV, a prospective study
in a geographical cohort is required.
Conclusions
Electrocardiographic features show a signiﬁcant correlation with
risk of sudden death in HCM-patients, and provide an additional
and conveniently accessible tool for the early identiﬁcation of high-
risk patients for appropriate therapy. Because of sizeable gender
differences in normal values for chest-lead-based ECG-amplitudes,
but not for limb-lead-based ECG amplitude sums, the limb-lead
amplitude sums, limb-lead amplitude–duration products, and a
risk score incorporating morphological changes provide the best
tools for ECG-screening for high-risk patients with HCM. T-wave
inversion, particularly in precordial leads, denotes a high-risk
status in young normotensive HCM-patients. The cut-off values
proposed here offer considerably higher odds ratios and sensitivity,
and better NPVs, than previously described risk factors for sudden
death in adult HCM. For example, sensitivity for limb-lead ampli-
tude–duration product  0.7 mV s has an odds ratio of 31.5
[6.9–143] and a sensitivity of 93% [78–99%] vs. an odds ratio of
5.1 [0.9–26.3] and a sensitivity of only 20% [4–48%] for the com-
monly used risk factor of .3 cm maximal wall thickness. As the
PPVs were similar, 54 vs. 50%, we therefore propose that ECG-
features should be included in routine risk-stratiﬁcation of HCM
patients.
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Supplementary material is available at European Heart Journal
online.
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